Epilepsy Market is expected to reach US$ 10.7 billion by 2030

Publisher: The Insight Partners

Oral Segment to Lead Epilepsy Market Based on Route of Administration During 2022–2030

According to our new research study on “Epilepsy Market Forecast to 2030 – Global Analysis – by Type, Route of Administration, Treatment Type, Age Group, Distribution Channel, and Geography,” the market was valued at US$ 7.7 billion in 2022 and is projected to reach US$ 10.7 billion by 2030; it is expected to register a CAGR of 4.1% from 2022 to 2030. Key factors driving the market growth include the rising prevalence of epilepsy and increasing investments in the development of epilepsy therapies. However, the recall of products hinders the growth of the market. Further, the development of gene therapy as a promising treatment approach is expected to bring new epilepsy market trends in the coming years.

Growing awareness about epilepsy and its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness of the condition and available treatments. In the US, Epilepsy Awareness Day or Purple Day is observed on March 26 every year to raise public understanding of the brain disorder, along with eliminating its fear and stigma. Similarly, November is reserved as National Epilepsy Awareness Month (NEAM) in the US every year to educate people about the condition and symptoms of epilepsy and raise funds for research related to the management of this disease.

Epilepsy Market, by Region, 2022(%)

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @ https://www.theinsightpartners.com/sample/TIPRE00016405

Source: The Insight Partners Analysis

The Epilepsy Foundation selects a theme that focuses on encouraging people to collaborate and act to promote awareness and funds for epilepsy. In November 2021, the foundation launched the #RemoveTheFilter social media campaign to reduce fear associated with epilepsy and bring hope to those suffering from the condition. Moreover, in partnership with SK Life Science Inc., the Epilepsy Foundation introduced a 30-minute on-demand course for people to learn the essentials of seizure first aid. In the UK, October 23 is reserved as the Sudden Unexpected Death in Epilepsy (SUDEP) Awareness Day. The SUDEP action leads the international epilepsy community to recognize and raise awareness about sudden and unexpected deaths caused by epilepsy. Thus, such initiatives and awareness campaigns increase epilepsy diagnoses and treatments, generating lucrative growth opportunities for the expansion of the epilepsy market size.

Epilepsy Market Analysis Based on Segments:

Based on type, the market is segmented into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In 2022, the generalized epilepsy segment held a significant epilepsy market share. It is expected to register the fastest CAGR in the market from 2022 to 2030. Generalized epilepsy involves widespread electrical disruptions in the brain from the outset. The condition can frequently impact both sides of the body, causing the loss of consciousness. The goal of therapeutics for generalized epilepsy is to regulate and prevent the brain's excessive electrical activity. These therapeutics may contain medications that target both the cortex and deep brain areas. AEDs are widely adopted for the treatment of this type of epilepsy.

Based on the route of administration, the market is segmented into oral, parenteral, and others. In 2022, the oral segment held a significant epilepsy market share. The same segment is expected to register the highest CAGR during 2022–2030. Oral administration is a prominent route of AED administration, especially among patients with chronic epilepsy. Oral AEDs primarily include immediate-release and modified-release (delayed-release and extended-release) dosage formulations. Oral medications confer the ease of use, allowing patients to self-administer and adhere to prescribed regimens. This route is favored for its simplicity compared to other administration routes, such as intramuscular and intravenous injections.

The geographic scope of the epilepsy market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the fastest CAGR in the market from 2022 to 2030. The growing number of people affected with epilepsy, the increasing aging population, and the rising number of product approvals are projected to benefit the Asia Pacific epilepsy market during the forecast period. China and Japan are the major contributors to the growth of the market in the region.

According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively. China is the most populated country in the world, recording the highest number of patients with neurological disorders. According to the Centers for Disease Control and Prevention, in China, the prevalence rate of active epilepsy ranges from 0.48% to 8.5%; there are 9 million people with epilepsy in Mainland China, two-thirds of whom are children. Antiepileptic drugs (AEDs) that are currently available in the market show no effect on seizures occurring in nearly 30% of epilepsy patients. The significant unmet medical needs associated with the disease fuel the epilepsy market growth.  

In August 2021, Eisai Co., Ltd. obtained two additional approvals of the AED Fycompa as a monotherapy from the National Medical Products Administration. First, the product was approved for its use as an adjunctive treatment or a monotherapy in pediatric cases for partial onset seizures in epilepsy patients aged 4 years and above. Second, it was approved as an adjunctive treatment for partial-onset seizures with or without secondary generalized seizures in epilepsy patients aged 12 or older. The growing number of drug approvals in China is propelling the epilepsy market growth.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, CombiGene AB, Livanova PLC, Novartis AG, Medtronic PLC, GSK PLC, and H. Lundbeck AS are among the leading companies profiled in the epilepsy market report.  

Based on type, the epilepsy market is categorized into progressive myoclonic epilepsy, generalized epilepsy, reflex epilepsy, and others. In terms of route of administration, the market is classified into oral, parenteral, and others. The market, by treatment type, is segmented into first-generation drugs, second-generation drugs, and third-generation drugs. In terms of age group, the epilepsy market is bifurcated into adults and children. Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and others. Based on geography, the epilepsy market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Contact Person: Content Team 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com